JMDC boosts revenue and dividend as profit slips, eyes further growth in FY2027

JMDC Inc. ( (JP:4483) ) has shared an announcement.

JMDC reported consolidated revenue of ¥50.46 billion for the year to March 31, 2026, up 20.9% as it expanded its healthcare data and analytics operations, with operating profit rising 20.7% to ¥10.52 billion and EBITDA improving to ¥13.18 billion. Despite this top-line growth, profit attributable to owners of the parent fell 7.0% to ¥6.77 billion and basic earnings per share softened, reflecting profit margin pressure even as the company raised its annual dividend to ¥18 per share and increased total assets and equity.

Operating cash flow declined to ¥8.59 billion while investing outflows widened, leading to a lower year-end cash balance, but JMDC signaled continued growth by forecasting a further near-20% rise in revenue to ¥60.5 billion and higher operating profit in the fiscal year ending March 2027. The guidance suggests the company expects sustained demand for its healthcare data services and incremental profitability, which, combined with a higher dividend and solid equity ratio above 50%, indicates confidence in its medium-term growth trajectory for investors and other stakeholders.

The most recent analyst rating on (JP:4483) stock is a Buy with a Yen4460.00 price target. To see the full list of analyst forecasts on JMDC Inc. stock, see the JP:4483 Stock Forecast page.

More about JMDC Inc.

JMDC Inc. is a Japan-based healthcare data and analytics company listed on the Tokyo Stock Exchange. The group focuses on medical data, insurance analytics and related healthcare IT services, targeting insurers, medical institutions and corporate customers seeking to improve healthcare efficiency and cost management.

Average Trading Volume: 449,673

Technical Sentiment Signal: Sell

Current Market Cap: Yen219.9B

For a thorough assessment of 4483 stock, go to TipRanks’ Stock Analysis page.